CORRECTION Open Access

## Correction to: The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/µL: evidence based on a meta-analysis



Yao Li<sup>1,2†</sup>, Xiaojie Huang<sup>2†</sup>, Hui Chen<sup>3</sup>, Yuanyuan Qin<sup>1,2</sup>, Jianhua Hou<sup>2</sup>, Aixin Li<sup>2</sup>, Hao Wu<sup>2</sup>, Xiaofeng Yan<sup>4</sup> and Yaokai Chen<sup>1\*</sup>

Correction to: BMC Infect Dis 20, 410 (2020) https://doi.org/10.1186/s12879-020-05126-z

Following publication of the original article [1], the authors identified an error in Fig. 3. The correct figure is given below.

The original article [1] has been corrected.

The original article can be found online at https://doi.org/10.1186/s12879-020-05126-z.

<sup>&</sup>lt;sup>1</sup>Division of infectious Diseases, Chongqing Public Health Medical Center, 109 Baoyu Road, Shapingba District, Chongqing 400036, China





© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>\*</sup> Correspondence: yaokaichen@hotmail.com

<sup>&</sup>lt;sup>†</sup>Yao Li and Xiaojie Huang contributed equally to this work.

Li et al. BMC Infectious Diseases (2021) 21:604 Page 2 of 2




Fig. 3 Forest plots of incidence of CM among CrAg + persons receiving azole vs. no intervention or placebo. Abbreviations: M-H, Mantel Haenszel; CI, confidence interval. ("Azole inter" means "Azole drug intervention", "No inter or plac" mean "No intervention or placebo"

## Author details

<sup>1</sup>Division of infectious Diseases, Chongqing Public Health Medical Center, 109 Baoyu Road, Shapingba District, Chongqing 400036, China. <sup>2</sup>Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China. <sup>3</sup>School of Biomedical Engineering, Capital Medical University, Beijing, China. <sup>4</sup>Section of Medical Affairs Administration, Chongqing Public Health Medical Center, Chongqing, China.

## Published online: 24 June 2021

## Reference

 Li, et al. The prevalence of cryptococcal antigen (CrAg) and benefits of preemptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/µL: evidence based on a meta-analysis. BMC Infect Dis. 2020;20:410. https://doi.org/10.1186/s12879-020-05126-z.